ロード中...
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of a...
保存先:
| 出版年: | Hepat Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338920/ https://ncbi.nlm.nih.gov/pubmed/32647565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2020-0004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|